menu
    • menu

    Company profile for Skyepharma

    NEW Drugs in Dev: 2
    Skyepharma-PSE
    News
    Skyepharma French CDMO Drives Growth Through Leadership Change

    06 Nov 2025

    // PRESS RELEASE

    Skyepharma Expands Oncology Operational Facility in France

    16 May 2025

    // PRESS RELEASE

    Skyepharma CDMO makes debut at Nordic Life Science Days

    23 Nov 2023

    // PHARMA NETWORKING

    DATA COMPILATION
    #PharmaFlow

    Skyepharma RM

    Contact Supplier

    Website

    Cosmoprof

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/GQ0e9Im32aY?si=o0xfkcMVN68jYcuM

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

    Related CompaniesRelated Companies

    About

    Skyepharma Production SAS is an expert & innovative CDMO in complex OSDs possessing its proprietary technologies of modified release & multilayer tablets. It offers a broad range of services, from early-stage development to industrial manufacturing & packaging. It also has the capacity for oncologic product development & manufacturing, as well as for NCEs, Highly potent molecules, non-sexual hormones, controlled substances, biotechnologies & others. Skyepharma has a proven record of successful projects, with a skilled scientific team which is agile and high-quality oriented. Skyepharma is GMP certified as well as FDA, ANSM & ANVISA approved.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SkyepharmaFrance Flag
    Country
    Country
    France
    Address
    Address
    55 Rue du Montmurier, 38070 Saint-Quentin-Fallavier
    Telephone
    Telephone
    +33 474952020
    Client Email
    Email
    info@skyepharma.com
    Client Website
    Website
    https://www.skyepharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/skyepharma/
    youtube
    YouTube
    https://www.youtube.com/channel/UCSj2WQGvNTrJr6vBqGo_rhA
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof

    Cosmoprof

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    “Skyepharma: the specialized CDMO growing in double digits”

    mic“Skyepharma: the specialized CDMO growing in double digits”

    This week, SpeakPharma interviews David Lescuyer, CEO, and Benoit Mougeot, CFO, of Skyepharma, a fully integrated French CDMO for complex oral solid dosage forms. Over the last six years, Skyepharma has transformed itself from a basic contract manufacturing organization (CMO) to an agile, expert, and differentiated contract development and manufacturing organization (CDMO). Continuous, proactive and major capital investments and a strong people-based unique expertise have generated double-digit growth for Skyepharma over the past five years. Skyepharma is now actively working on building stronger partnerships to constantly improve the supply chain of the health industry and the lives of many patients.Over the last six years, Skyepharma has truly transformed itself from a CMO to an agile CDMO. Can you briefly take us through this journey?Lescuyer: Yes, the last few years have been quite eventful. We initiated this journey in 2016, to establish a first-in-class expert CDMO. In 2021, further to the successful completion of a MBO (short for management buyout), Skyepharma became a 100 percent French-owned independent CDMO, owned by its management team, which has more than 150 years of cumulative experience in the pharmaceutical business and a proven expertise in the CDMO business. Over the last two years, we have emerged as a key player in the development of oral solid drugs and the delivery of oral complex technologies. We are experiencing double-digit growth.Such a transformation could not have been easy. Can you tell us what were some of the things Skyepharma relied on to bring about this change?Mougeot: Our transformation and growth have leaned on two strong pillars.The first is the development of our people. The company has invested a lot in skilling up our people and establishing a strong and specific organizational culture. As a result, we are offering a recognized customer experience to our partners, where agility, reduced time-to-market and breakthrough innovation are key differentiators.The second pillar is our capital investment strategy. We deployed an investment to the tune of €40 million (US$ 42 million) between 2016 and 2023. This investment is being used not only to revamp our manufacturing and development suites but also to upgrade our FDA-approved facility and to tremendously expand our development and production capabilities with, for instance, the design and building of two new, state-of-the-art areas fully-dedicated to highly potent molecules, including oncology. This way, we will keep offering more support to our partners for their high-value projects.You said Skyepharma has been growing in double digits. Did Covid-19 impact your growth?Mougeot: We have been successful in building a resilient model that was able to withstand the Covid years.Given the macroeconomic context, we have been leaning on a strong operational organization and leadership team, resulting in a continuous premium service level that was kept high during the pandemic.This is what we mean by customer experience!Lescuyer: Our approach is to be a “PDMO”, wherein “P” stands for partner, that focuses on long-term partnerships. Anticipating the unmet needs of our partners throughout the supply chain and early in their development programs, there’s now a world of opportunities for innovative and reliable companies in the CDMO marketplace.Our organic growth strategy relies on our expertise for complex and hard-to-make drugs and in our ability to keep investing in science and added-value capabilities, such as high-potency drugs. Innovative initiatives such as our proprietary Skyehub model, the expansion of our proprietary technologies’ portfolio and related IP (intellectual property), and academic partnerships are just some of the ways in which we are differentiating ourselves from other CDMOs.What is the Skyehub model? Can you elaborate on this initiative?Lescuyer: Skyehub is part of our strategic opportunities for adjacencies. France and Europe are dramatically missing large-scale clinical and commercial capacities for bioproduction. We have decided to allocate 10,000 square meters of our real estate close to Lyon to build and run dedicated facilities for biotech companies looking for such capacity. We take care of the construction and certification of the related buildings. The resident companies will benefit from our industrial expertise, from our quality systems, while also allowing them the opportunity to run their production with their own staff.In February 2022, we entered into a partnership with MaaT Pharma to establish the first cGMP manufacturing facility dedicated to microbiome ecosystem therapies in France, the largest such facility in Europe. Through this partnership, we will provide MaaT Pharma with a dedicated 1,700+ square meter biotech plant, with the potential to double if needed. This will support the clinical and commercial development of MaaT’s most advanced assets – MaaT013 and MaaT033. It will also support the expansion of R&D manufacturing capacities for the development of its new drug (MaaT03x).Other partnerships will be signed, focusing on microbiome-based therapies or other innovative biotechnologies.More than just bioproduction capacity, our proprietary Skyehub model is clearly a value accelerator for our partners.Where does Skyepharma go from here? Tell us about your future plans.With our highly skilled team, experienced in transforming sites into centers of excellence, we have been able to build strong partnerships and extensive collaborations with our existing clients, while also taking on new partners. We offer seamless and adapted solutions support for the most demanding projects from our partners by utilizing our capacity, services and expertise, focusing on reducing time to market.Skyepharma is now the preferred supplier for quite a few pharma companies, ranging from virtual pharmaceutical companies (VPCs) to Big Pharma. Having invested twice our yearly revenue over the past five years, Skyepharma will now continue to leverage its differentiators to keep growing and remain the solution provider for pharma companies facing strong supply and technical challenges in complex oral solid dosage (OSD) and biotech spaces. 

    Impressions: 3012

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/a-differentiated-expert-and-agile-cdmo-player-in-the-osd-market

    #SpeakPharma With Skyepharma
    18 Jan 2023
    Share info Share

    CORPORATE CONTENT #SupplierSpotlight

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-84876.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    French CDMO Drives Growth Through Leadership Change

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-29806.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Skyepharma Strengthens Oncology with New France Facility

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-69130.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Controlling Lag-time & Release Kinetics of Press-coated Tablets

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-20701.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Microfluidization - Skyepharma Collaboration with Lyon University

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-1652421761.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-35695.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Leading Pharmaceutical Development in a Sustainable Way

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-1647412480.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Skyepharma & MaaT Pharma launches a facility for Biotherapies

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-1646369243.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-1647862827.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Quality By Design & Expertise

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-1551421586.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Compaction Simulation Expertise

    read-more

      https://www.pharmacompass.com/pdf/party/content/skyepharma-party-content-1551421802.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 8980

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Skyepharma French CDMO Drives Growth Through Leadership Change
    Skyepharma French CDMO Drives Growth Through Leadership Change

    06 Nov 2025

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/skyepharma-advance-strategic-growth-through-leadership-transition-40143.pdf

    PRESS RELEASE
    06 Nov 2025
    Share Share
    Skyepharma Expands Oncology Operational Facility in France
    Skyepharma Expands Oncology Operational Facility in France

    16 May 2025

    // PRESS RELEASE

    https://www.pharmacompass.com/pdf/news/skyepharma-expands-oncology-operational-facility-in-france-1137.pdf

    PRESS RELEASE
    16 May 2025
    Share Share
    Skyepharma CDMO makes debut at Nordic Life Science Days
    Skyepharma CDMO makes debut at Nordic Life Science Days

    23 Nov 2023

    // PHARMA NETWORKING

    https://www.pharmaceutical-networking.com/skyepharma-cdmo-makes-debut-at-nordic-life-science-days/

    PHARMA NETWORKING
    23 Nov 2023
    Share Share
    Biophytis And Skyepharma Sign A Partnership Agreement For Bio101
    Biophytis And Skyepharma Sign A Partnership Agreement For Bio101

    25 Sep 2023

    // PRESS RELEASE

    https://www.biophytis.com/en/biophytis-and-skyepharma-sign-a-partnership-agreement-for-the-production-of-sarconeos-bio101/

    PRESS RELEASE
    25 Sep 2023
    Share Share
    MaaT &Skyepharma Complete Construction of Largest Manufacturing
    MaaT &Skyepharma Complete Construction of Largest Manufacturing

    12 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230911074606/en

    BUSINESSWIRE
    12 Sep 2023
    Share Share
    EureKING Signs Put Option To Acquire Skyepharma, EU Bio-CDMO
    EureKING Signs Put Option To Acquire Skyepharma, EU Bio-CDMO

    31 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/30/2678833/0/en/eureKING-the-first-European-SPAC-in-healthcare-dedicated-to-biomanufacturing-announces-the-signature-of-a-put-option-for-the-potential-acquisition-of-Skyepharma-to-build-a-new-Euro.html

    GLOBENEWSWIRE
    31 May 2023
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mundipharma, Vectura Plan to Reformulate flutiform® to Reduce Carbon Footprint

    Details:

    Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.


    Lead Product(s): Fluticasone Propionate,Formoterol Fumarate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Flutiform

    Study Phase: Approved FDFProduct Type: Steroid

    Recipient: Mundipharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration April 16, 2024

    Skyepharma Company Banner

    01

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Recipient : Mundipharma

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Mundipharma, Vectura Plan to Reformulate flutiform® to Reduce Carbon Footprint

    Details : Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.

    Product Name : Flutiform

    Product Type : Steroid

    Upfront Cash : Undisclosed

    April 16, 2024

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mundipharma and Vectura announce plans to reformulate flutiform®

    Details:

    The collaboration aims to reformulate flutiform (fluticasone propionate/formoterol fumarate) used in a pressurised metered-dose inhaler. It is being indicated for asthma.


    Lead Product(s): Fluticasone Propionate,Formoterol Fumarate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Flutiform

    Study Phase: Approved FDFProduct Type: Steroid

    Recipient: Mundipharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration April 16, 2024

    Skyepharma Company Banner

    02

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Recipient : Mundipharma

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Mundipharma and Vectura announce plans to reformulate flutiform®

    Details : The collaboration aims to reformulate flutiform (fluticasone propionate/formoterol fumarate) used in a pressurised metered-dose inhaler. It is being indicated for asthma.

    Product Name : Flutiform

    Product Type : Steroid

    Upfront Cash : Undisclosed

    April 16, 2024

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSkyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

    Biophytis and Skyepharma Sign a Partnership Agreement for The Production of Sarconeos (BIO101)

    Details:

    Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.


    Lead Product(s): 20-Hydroxyecdysone

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Sarconeos

    Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous

    Sponsor: Biophytis

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership September 25, 2023

    Skyepharma Company Banner

    03

    Skyepharma

    France
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSkyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

    Lead Product(s) : 20-Hydroxyecdysone

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Biophytis

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Biophytis and Skyepharma Sign a Partnership Agreement for The Production of Sarconeos (BIO101)

    Details : Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.

    Product Name : Sarconeos

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    September 25, 2023

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSkyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

    MaaT and Skyepharma Partner for First Microbiome cGMP Site in France

    Details:

    Through the parternship, MaaT Pharma will increase the manufacturing capacities ten-fold in order to support clinical and commercial development of MaaT013 for the treatment of GvHD.


    Lead Product(s): MaaT013

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Protein

    Sponsor: MaaT Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership February 08, 2022

    Skyepharma Company Banner

    04

    Skyepharma

    France
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSkyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

    Lead Product(s) : MaaT013

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : MaaT Pharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    MaaT and Skyepharma Partner for First Microbiome cGMP Site in France

    Details : Through the parternship, MaaT Pharma will increase the manufacturing capacities ten-fold in order to support clinical and commercial development of MaaT013 for the treatment of GvHD.

    Product Name : Undisclosed

    Product Type : Protein

    Upfront Cash : Undisclosed

    February 08, 2022

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury

    Details:

    Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicological studies.


    Lead Product(s): Cannabidiol,Isoflurane

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Controlled Substance

    Sponsor: Incannex Healthcare

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement June 22, 2021

    Skyepharma Company Banner

    05

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cannabidiol,Isoflurane

    Therapeutic Area : Trauma (Emergency, Injury, Surgery)

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Incannex Healthcare

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatme...

    Details : Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicolog...

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Undisclosed

    June 22, 2021

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment

    Details:

    IPA-001 is inhaled formulation displayed viricidal activity against SARS-CoV2 after 5 minutes contact time. It is purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 virus in vitro.


    Lead Product(s): IPA-001

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Miscellaneous

    Sponsor: Inspira

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement May 06, 2021

    Skyepharma Company Banner

    06

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : IPA-001

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : Inspira

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment

    Details : IPA-001 is inhaled formulation displayed viricidal activity against SARS-CoV2 after 5 minutes contact time. It is purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 ...

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    May 06, 2021

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Vectura Highlights Update Made by Hikma on Launch of Generic Advair Diskus®

    Details:

    Hikma will immediately resume launch activities of its generic product for Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.


    Lead Product(s): Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Fluticasone Propionate/Salmeterol-Generic

    Study Phase: Approved FDFProduct Type: Steroid

    Sponsor: Hikma Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 21, 2021

    Skyepharma Company Banner

    07

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Hikma Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vectura Highlights Update Made by Hikma on Launch of Generic Advair Diskus®

    Details : Hikma will immediately resume launch activities of its generic product for Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.

    Product Name : Fluticasone Propionate/Salmeterol-Generic

    Product Type : Steroid

    Upfront Cash : Inapplicable

    April 21, 2021

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Vectura Earns $11m Milestone as Hikma Receives US FDA Approval for Generic Advair Diskus®

    Details:

    The new device is an evolution of Vectura’s lever-operated multi-dose (LOMI) device and builds on Vectura and Hikma’s shared experience with the generic Advair Diskus® programme, enabling accelerated development under this agreement.


    Lead Product(s): Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Fluticasone Propionate/Salmeterol-Generic

    Study Phase: Approved FDFProduct Type: Steroid

    Sponsor: Hikma Pharmaceuticals

    Deal Size: $95.0 million Upfront Cash: $15.0 million

    Deal Type: Agreement December 17, 2020

    Skyepharma Company Banner

    08

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Hikma Pharmaceuticals

    Deal Size : $95.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Vectura Earns $11m Milestone as Hikma Receives US FDA Approval for Generic Advair Diskus®

    Details : The new device is an evolution of Vectura’s lever-operated multi-dose (LOMI) device and builds on Vectura and Hikma’s shared experience with the generic Advair Diskus® programme, enabling accelerated development under this agreement.

    Product Name : Fluticasone Propionate/Salmeterol-Generic

    Product Type : Steroid

    Upfront Cash : $15.0 million

    December 17, 2020

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Vectura Signs Agreement with Kinaset Therapeutics Inc. to Support the Development of VR588 to Treat Asthma

    Details:

    This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.


    Lead Product(s): VR588

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Recipient: Kinaset Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement November 30, 2020

    Skyepharma Company Banner

    09

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VR588

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase I

    Recipient : Kinaset Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Vectura Signs Agreement with Kinaset Therapeutics Inc. to Support the Development of VR588 to Trea...

    Details : This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    November 30, 2020

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Status Update on VR315 (US)

    Details:

    Fluticasone Propionate / Salmeterol or VR315 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.


    Lead Product(s): Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Fluticasone Propionate/Salmeterol-Generic

    Study Phase: Approved FDFProduct Type: Steroid

    Sponsor: Hikma Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 22, 2020

    Skyepharma Company Banner

    10

    Vectura Ltd

    United Kingdom
    arrow
    IPPE
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Hikma Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Status Update on VR315 (US)

    Details : Fluticasone Propionate / Salmeterol or VR315 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.

    Product Name : Fluticasone Propionate/Salmeterol-Generic

    Product Type : Steroid

    Upfront Cash : Inapplicable

    September 22, 2020

    Skyepharma Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Services

    Discover the service capabilities from this company

    Analytical

    Discover their expertise for : Analytical

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    Sales, Marketing, Registration

    Discover their expertise for : Sales, Marketing, Registration

    Packaging

    Discover their expertise for : Packaging

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Skyepharma full-view

    TOP RANKED SUPPLIER FOR:

    Formulation Development Services of Modified Release forms
    full-view
    Manufacturing Vaccines
    full-view
    Potent Compounds Capsules
    full-view
    Tablet coating
    full-view
    Diffucaps® Customized Release Technology
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search